The End the Vaccine Carveout Act would expose vaccine makers to lawsuits that once drove companies out of the industry.
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
In a highly unusual move for a normally buttoned-up regulatory agency, a senior official with the US Food and Drug ...
Vietnam has launched clinical trials of a new antiviral drug that could offer fresh hope in the fight against dengue fever, a ...
Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at ...
In Vietnam, dengue fever consistently records cyclical increases, especially during the rainy season. In recent years many ...
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But ...
But just a week later, on Feb. 18, the FDA backtracked on its decision, saying that it will indeed review the vaccine, potentially in time for its approval for the ...
The FDA approved a vaccine for mumps nearly 60 years ago, so why are some areas of the United States experiencing outbreaks ...
Southwest Baltimore sits in the heart of the city’s “Black Butterfly,” where history, access, and lived environment continue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results